Iota-carrageenan extracted from red algae is a potent inhibitor of SARS‐CoV-2 infection in reconstituted human airway epithelia
David Bovard, Marco Van Der Toorn, Walter K Schlage, Samuel Constant, Kasper Renggli, Manuel C Peitsch, Julia Hoeng
Biochemistry and Biophysics Reports, doi:10.1016/j.bbrep.2021.101187
Iota-carrageenan (IC) nasal spray, a medical device approved for treating respiratory viral infections, has previously been shown to inhibit the ability of a variety of respiratory viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to enter and replicate in the cell by interfering with the virus binding to the cell surface. The aim of this study was to further investigate the efficacy and safety of IC in SARS-CoV-2 infection in advanced in vitro models of the human respiratory epithelium, the primary target and entry port for SARS-CoV-2. We extended the in vitro safety assessment of nebulized IC in a 3-dimensional model of reconstituted human bronchial epithelium, and we demonstrated the efficacy of IC in protecting reconstituted nasal epithelium against viral infection and replication of a patient-derived SARS-CoV-2 strain. The results obtained from these two advanced models of human respiratory tract epithelia confirm previous findings from in vitro SARS-CoV-2 infection assays and demonstrate that topically applied IC can effectively prevent SARS-CoV-2 infection and replication. Moreover, the absence of toxicity and functional and structural impairment of the mucociliary epithelium demonstrates that the nebulized IC is well tolerated.
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Baxter, Targeted omics analyses, and metabolic enzyme activity assays demonstrate maintenance of key mucociliary characteristics in long term cultures of reconstituted human airway epithelia, Toxicol. Vitro
Bichiri, Rente, Jesus, Safety and efficacy of iota-carrageenan nasal spray in treatment and prevention of the common cold, Med Pharm Rep
Bovard, A lung/liver-on-a-chip platform for acute and chronic toxicity studies, Lab Chip
Bovard, Comparison of the basic morphology and function of 3D lung epithelial cultures derived from several donors, Current Research in Toxicology
Burton, Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them, Cochrane Database Syst. Rev
Burton, Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection, Cochrane Database Syst. Rev
Colafrancesco, COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome?, Autoimmun. Rev
Eccles, Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold, Respir. Res
Ecdc, COVID-19 situation update worldwide, as of week
Fazekas, Lessons learned from a double-blind randomised placebocontrolled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold, BMC Compl. Alternative Med
Giovane, Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: a review, Rev. Med. Virol
Graf, Development of a nasal spray containing xylometazoline hydrochloride and iota-carrageenan for the symptomatic relief of nasal congestion caused by rhinitis and sinusitis, Int. J. Gen. Med
Grassauer, Iota-Carrageenan is a potent inhibitor of rhinovirus infection, Virol. J
Hamming, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol
Hemilä, Chalker, Influenza Virus Infections: Re-analysis of Randomized Trial Data
Hu, Characteristics of SARS-CoV-2 and COVID-19, Nat. Rev. Microbiol
Huang, Wiszniewski, Constant, The use of in vitro 3D cell models in drug development for respiratory diseases
Iskandar, 3-D nasal cultures: systems toxicological assessment of a candidate modified-risk tobacco product, ALTEX
Iverson, Leveraging 3D model systems to understand viral interactions with the respiratory mucosa, Viruses
Kavanagh, Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19, Med. Hypotheses
Kim, Read, Fauci, Therapy for early COVID-19: a critical need, Jama
Koenighofer, Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials, Multidiscip Respir Med
Leibbrandt, Iota-carrageenan is a potent inhibitor of influenza A virus infection, PLoS One
Lenz, A dose-controlled system for air-liquid interface cell exposure and application to zinc oxide nanoparticles, Part. Fibre Toxicol
Ludwig, Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial, Respir. Res
Morokutti-Kurz, Graf, Prieschl-Grassauer, Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat, Int. J. Gen. Med
Morokutti-Kurz, Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro, PLoS One
Pizzorno, Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia, Cell Rep Med
Sanders, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, Jama
Schütz, Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures, Am. J. Physiol. Lung Cell Mol. Physiol
Srinivasan, TEER measurement techniques for in vitro barrier model systems, J. Lab. Autom
Stathis, Review of the use of nasal and oral antiseptics during a global pandemic, Future Microbiol
Zou, SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N. Engl. J. Med
